For the production of 3 custom antibodies and protein associated with antibody production.
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $17,064
Award facts
- Contract value 100% obligated
- $17,064.17 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621991 Blood and Organ Banks
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$142 | |
| Original award | $17,206 |
About this award
The National Cancer Institute awarded a $17,064.17 firm fixed price contract to Genscript USA Inc. under a Blanket Purchase Agreement (BPA) call for the production of three custom antibodies and associated proteins required for antibody production. The award was made on November 18, 2019, with an ultimate completion date of January 3, 2025. The contract was processed to de-obligate expiring FY20 funding lines in accordance with NIH Office of Administrative Law and Management (OALM) Communication 25-06. No small business set-aside was used for this procurement, and the work is to be performed in Piscataway, New Jersey.
Genscript USA Inc., a biotechnology company specializing in advanced molecular biology services and custom biological research materials, is well-positioned to deliver these antibody production services. The company, headquartered in Piscataway, has been registered in the System for Award Management since July 2013 and has established a strong track record providing gene synthesis, protein production, and antibody development services to multiple federal agencies including the NIH, Centers for Disease Control and Prevention, and Food and Drug Administration. This BPA call represents continued partnership between the National Cancer Institute and Genscript to support critical research capabilities in antibody development.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on November 18, 2019.
How much is contract 75N91020F00001 worth?
The government has obligated $17,064 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a BPA call under HHSN263201400039B, a blanket purchase agreement.
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award